Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Urothelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Transitional Cell Neoplasm
Urothelial Neoplasm

Subtype

Urothelial Neoplasm

CI-CAN-00001629Explore in graph →

Non-malignant236 active trials5 approved drugs8 evidence items

NCIt: C39852

Overview
Statistics
Survival
Genomics24
Variants & evidence8
Drugs6
Trials625
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (24)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 26, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–24 of 24 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.
· Cancer Epidemiol Biomarkers Prev · 2005 · PMID 15824158 · validated civic_curation pubmed
Genome sequencing identifies a basis for everolimus sensitivity.
· Science · 2012 · PMID 22923433 · validated civic_curation pubmed
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.
· Clin Cancer Res · 2021 · PMID 34074656 · validated civic_curation pubmed
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.
· Clin Cancer Res · 2020 · PMID 32636318 · validated civic_curation pubmed
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed
Damrauer et al. Nat Commun. 2022
· 2022 · PMID 36333289 · validated cbioportal_study pubmed
Guo et al. Nat Genet 2013
· 2013 · PMID 24121792

Showing 1–24 of 24 publications

· validated cbioportal_study

Faltas and Prandi, Nature Genetics 2016

· 2016 · PMID 27749842 · validated cbioportal_study pubmed

Van Allen et al. Cancer Discov 2014

· 2014 · PMID 25096233 · validated cbioportal_study pubmed

Iyer, Gopa et al. JCO precision oncology 2024

· 2024 · PMID 39499893 · validated cbioportal_study pubmed

Brendan J et al. Eur Urol Open Sci 2025

· 2025 · PMID 40256659 · validated cbioportal_study pubmed

Pietzak et al. Eur Urol 2019

· 2019 · PMID 30290956 · validated cbioportal_study pubmed

Iyer et al. J Clin Oncol 2013

· 2013 · PMID 23897969 · validated cbioportal_study pubmed

Kim et al. Eur Urol 2015

· 2015 · PMID 25092538 · validated cbioportal_study pubmed

Pietzak et al. Eur Urol 2017

· 2017 · PMID 28583311 · validated cbioportal_study pubmed

Al-Ahmadie et al. Nat Genet 2016

· 2016 · PMID 26901067 · validated cbioportal_study pubmed

TCGA, Nature 2014

· 2014 · PMID 24476821 · validated cbioportal_study pubmed

Robertson et al. Cell 2017

· 2017 · PMID 28988769 · validated cbioportal_study pubmed

Robinson et al. Nat Commun 2019

· 2019 · PMID 31278255 · validated cbioportal_study pubmed

Xiaoping et al. Genome Biology 2021

· 2021 · PMID 33397444 · validated cbioportal_study pubmed

Kwanghee et al. Nat Commun 2020

· 2020 · PMID 32332851 · validated cbioportal_study pubmed

Sfakianos et al. Eur Urol 2015

· 2015 · PMID 26278805 · validated cbioportal_study pubmed

Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma.

· JCO Precis Oncol · 2022 · PMID 35977348 · validated civic_curation pubmed